Immuneering Corporation Announces Grant of Inducement Award

Core Insights - Immuneering Corporation has appointed Igor Matushansky, M.D., Ph.D., as Chief Medical Officer, effective March 20, 2025 [1] - Dr. Matushansky received an option to purchase 118,000 shares of Class A common stock at an exercise price of $1.80, which is the closing price on March 21, 2025 [1] - The stock option has a ten-year term and vests 25% on March 17, 2026, with the remaining 75% vesting in equal monthly installments over three years, fully vesting by March 17, 2029 [1] Company Overview - Immuneering is a clinical-stage oncology company focused on developing and commercializing therapies for cancer patients [2] - The lead product candidate, IMM-1-104, is an oral MEK inhibitor aimed at improving tolerability and expanding indications for RAS-driven tumors, currently in a Phase 1/2a trial [2] - Another product candidate, IMM-6-415, is also a MEK inhibitor in a Phase 1/2a trial for advanced solid tumors with RAS or RAF mutations [2]